Biomerica (BMRA) Fundamentals 2026 — Revenue Analysis | SniperIQ

.63 on the NASDAQ. This SniperIQ fundamentals page covers Biomerica's valuation, profitability (net margin -96.5%), revenue ($5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Biomerica's market cap?

Biomerica (BMRA) has a market capitalization of approximately $5M, trading at

.63 on the NASDAQ. Market cap moves with the live share price.

What is Biomerica's P/E ratio?

Biomerica's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Biomerica?

Biomerica runs a net profit margin of -96.5%, a gross margin of 4.3%, and an operating margin of -123.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Biomerica generate?

Biomerica reported revenue of $5M for fiscal year 2025, with net income of -$5M and earnings per share (EPS) of -2.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Biomerica pay a dividend?

Biomerica does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Biomerica financially healthy?

Biomerica carries a debt-to-equity ratio of 0.06x and a current ratio of 2.64x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Biomerica a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Biomerica (BMRA) the key facts are: market cap $5M, revenue $5M, 52-week range 1.6-4.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.